Clinical Trials
19 trialsNCT05709171 2023-11-22
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Rigshospitalet, Denmark
Phase 2 Unknown
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown
NCT05113355 2021-11-24
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05076786 2021-11-03
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04427787 2021-09-05
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04491851 2020-11-05
Impact of Peptides and Chelators on Somatostatin Receptor Antagonists
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04194125 2020-11-04
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
University of Warmia and Mazury
Phase 2 Unknown
NCT04207463 2020-06-17
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04029428 2020-04-01
POLNETS_PRRT
University of Warmia and Mazury
Phase 2 Unknown
NCT00874614 2020-02-20
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Unknown
NCT03422029 2020-02-07
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
Peking University
Phase 2 Unknown
NCT03963193 2019-05-24
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Henan Cancer Hospital
Phase 2 Unknown
NCT03457844 2018-09-11
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT03279601 2017-09-12
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
Peking University
Phase 2 Unknown
NCT03204032 2017-06-29
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
ChineseAMS
Phase 2 Unknown
NCT02455596 2016-01-05
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2 Unknown
NCT02279758 2014-10-31
MetNet
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT01931488 2013-08-29
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT01203306 2010-09-16
XELBEVOCT
University of Turin, Italy
Phase 2 Unknown